Tag Archives: visfatin
The levels of visfatin and toll-like receptors in arterial hypertension and type 2 diabetes mellitus
N. Pokrovska1, S. Mahiiovych1, I. Fomenko2,
L. Biletska2, H. Sklyarova3, L. Kobylinska2*
1Department of Therapy No 1, Medical Diagnostics and Hematology and Transfusion
of FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
2Department of Biochemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
3Department of Family Medicine FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
*e-mail: lesyaivanivna.biochemistry@gmail.com
Received: 28 January 2024; Revised: 26 February 2024;
Accepted: 27 February 2024; Available on-line: 30 April 2024
Hypertension and type 2 diabetes mellitus (DM) remain widespread diseases that are becoming more prevalent. The role of visfatin and toll-like receptor (TLR) molecules in the pathogenesis of these diseases requires further research. Our aim was to study changes in visfatin and TLR levels in patients with hypertension and type 2 diabetes. Fifty-one patients were examined and divided into two groups: group 1 included 27 patients with hypertension and group 2 included 24 people with hypertension and type 2 DM. The control group included 18 practically healthy people. All individuals underwent general blood test, coagulogram, biochemical blood test, enzyme immunoassay to determine the level of visfatin and TLR in the blood serum and echocardiography. Hypertrophy of the walls of the left ventricle (LV) was observed in patients of two observed groups. The most common type of LV geometry was concentric hypertrophy (41.2%). The level of visfatin was significantly higher in patients of group 1, while in patients of group 2 it was decreased (P ˂ 0.05) and the level of TLR was increased (P ˂ 0.05). The elevated level of TLR in the serum of patients with hypertension can be considered a factor of low-grade inflammation, especially in combination with type 2 DM. The increase in the concentration of visfatin in hypertension serves as a more sensitive marker compared to TLR regarding the risk of developing comorbid cardiovascular pathology. The therapeutic treatments of patients with type 2 DM cause a reduction in the concentration of visfatin induced by hypertension.
Serum visfatin, resistin levels and inflammation markers in psoriasis patients
A. Majid*, M. Fouad
Department of Chemistry, College of Science, University of Thi-Qar, Thi-Qar, 64001, Iraq;
*e-mail: aliaa.s_mschem@sci.utq.edu.iq
Received: 08 October 2022; Revised: 02 December 2022;
Accepted: 17 February 2023; Available on-line: 27 February 2023
Psoriasis is a common chronic inflammatory skin condition that varies in severity. Psoriasis is associated with complex disorders, which incorporate metabolic syndrome, obesity and impaired glucose tolerance. Adipose tissue secretes several hormones and cytokines, in particular visfatin and resistin that could be involved in the development of psoriasis by acting as pro-inflammatory or immunoregulatory factors. The aim of this work was to evaluate the serum level of visfatin and resistin as well as of high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) in psoriatic patients. The study included 43 healthy individuals and 45 patients divided into three groups with mild, moderate and severe clinical degrees of disease assessed by the Psoriasis Area Severity Index (PASI). The results showed a significant increase in the concentration of serum visfatin, resistin, ESR and hs-CRP in patient groups in comparison with a control group. The highest increase in indicators was observed in the group of patients with severe disease compared with the mild and moderate patients groups. The significance of studied indicators as biomarkers of psoriasis disease severity is analyzed.